Risk–Benefit Analysis of Primary Prophylaxis Against Pneumocystis Jirovecii Pneumonia in Patients With Rheumatic Diseases Receiving Rituximab
Arthritis & Rheumatology · 2023-11 · 75 (11) · 2036-2044
DOI: 10.1002/art.42541 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis & Rheumatology, online erschienen am 22.08.2023. Verfasst von Jun Won Park und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Pneumonia, Pneumocystis, Rheumatic Diseases. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Objective
To identify a specific population of patients with rheumatic diseases receiving rituximab treatment for whom the benefit from primary prophylaxis against Pneumocystis jirovecii pneumonia (PJP) outweighs the risk of adverse events (AEs).
Methods
This study included 818 patients treated with rituximab for rheumatic diseases, among whom 419 received prophylactic trimethoprim/sulfamethoxazole (TMP/SMX) with rituximab, while the remainder did not. Differences in 1‐year PJP incidence between the groups were estimated using Cox proportional hazards regression. Risk–benefit assessment was performed in subgroups stratified according to risk factors based on the number needed to treat (NNT) to prevent 1 case of PJP and the number needed to harm (NNH) due to severe AEs. Inverse probability of treatment weighting was applied to minimize the confounding by indication.
Results
During the 663.1 person‐years, there were 11 PJP cases, with a mortality rate of 63.6%. Concomitant use of high‐dose glucocorticoids (≥30 mg/day of prednisone or equivalent during 4 weeks after rituximab administration) was the most important risk factor. The PJP incidence (per 100 person‐years) was 7.93 (95% confidence interval [95% CI] 2.91–17.25) in the subgroup receiving high‐dose glucocorticoids compared with 0.40 (95% CI 0.01–2.25) in the subgroup without high‐dose glucocorticoid use. Although prophylactic TMP/SMX significantly reduced the overall PJP incidence (HR 0.11 [95% CI 0.03–0.43]), the NNT to prevent 1 case of PJP (146) was higher than the NNH (86). In contrast, the NNT fell to 20 (95% CI 10.7–65.7) in patients receiving concomitant high‐dose glucocorticoids.
Conclusion
The benefit associated with primary PJP prophylaxis outweighs the risk of severe AEs in patients with rheumatic diseases receiving rituximab and concomitant high‐dose glucocorticoid treatment. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham.
- Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Republic of Korea.
- Division of Rheumatology, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University, Boramae Medical Center, Seoul, Republic of Korea.
- Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, and Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital,…
- Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, and Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Scienc…
ORCID-Profile: Jun Won Park, Jeffrey R Curtis, Eun Ha Kang, Yun Jong Lee, Eun Bong Lee
Förderung
- National Research Foundation of Korea
Zitieren
APA
Park, J. W., Curtis, J. R., Choi, S. R., Kim, M. J., Ha, Y. J., Kang, E. H., Lee, Y. J., & Lee, E. B. (2023). Risk–Benefit Analysis of Primary Prophylaxis Against Pneumocystis Jirovecii Pneumonia in Patients With Rheumatic Diseases Receiving Rituximab. Arthritis & Rheumatology, 75(11), 2036-2044. https://doi.org/10.1002/art.42541
Vancouver
Park JW, Curtis JR, Choi SR, Kim MJ, Ha YJ, Kang EH, et al. Risk–Benefit Analysis of Primary Prophylaxis Against Pneumocystis Jirovecii Pneumonia in Patients With Rheumatic Diseases Receiving Rituximab. Arthritis & Rheumatology. 2023;75(11):2036-2044. doi:10.1002/art.42541
BibTeX
@article{Park2023,
author = {Park, Jun Won and Curtis, Jeffrey R and Choi, Se Rim and Kim, Min Jung and Ha, You-Jung and Kang, Eun Ha and Lee, Yun Jong and Lee, Eun Bong},
title = {Risk–Benefit Analysis of Primary Prophylaxis Against Pneumocystis Jirovecii Pneumonia in Patients With Rheumatic Diseases Receiving Rituximab},
journal = {Arthritis & Rheumatology},
year = {2023},
volume = {75},
number = {11},
pages = {2036--2044},
doi = {10.1002/art.42541}
}
EUVIMED